| BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups ML Berres, KPH Lim, T Peters, J Price, H Takizawa, H Salmon, J Idoyaga, ... Journal of Experimental Medicine 211 (4), 669-683, 2014 | 427 | 2014 |
| Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis R Chakraborty, OA Hampton, X Shen, SJ Simko, A Shih, H Abhyankar, ... Blood, The Journal of the American Society of Hematology 124 (19), 3007-3015, 2014 | 424 | 2014 |
| Primary immunodeficiency diseases: genomic approaches delineate heterogeneous Mendelian disorders A Stray-Pedersen, HS Sorte, P Samarakoon, T Gambin, IK Chinn, ... Journal of Allergy and Clinical Immunology 139 (1), 232-245, 2017 | 279 | 2017 |
| Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis IK Chinn, OS Eckstein, EC Peckham-Gregory, BR Goldberg, LR Forbes, ... Blood, The Journal of the American Society of Hematology 132 (1), 89-100, 2018 | 176 | 2018 |
| Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis R Chakraborty, TM Burke, OA Hampton, DJ Zinn, KPH Lim, H Abhyankar, ... Blood, The Journal of the American Society of Hematology 128 (21), 2533-2537, 2016 | 144 | 2016 |
| Differentiating skin-limited and multisystem Langerhans cell histiocytosis SJ Simko, B Garmezy, H Abhyankar, PJ Lupo, R Chakraborty, KPH Lim, ... The Journal of pediatrics 165 (5), 990-996, 2014 | 120 | 2014 |
| CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH‐associated neurodegeneration and mass lesions KL McClain, J Picarsic, R Chakraborty, D Zinn, H Lin, H Abhyankar, ... Cancer 124 (12), 2607-2620, 2018 | 99 | 2018 |
| Survivin-specific T cell receptor targets tumor but not T cells C Arber, X Feng, H Abhyankar, E Romero, MF Wu, HE Heslop, P Barth, ... The Journal of clinical investigation 125 (1), 157-168, 2015 | 68 | 2015 |
| BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups ML Berres, KPH Lim, T Peters, J Price, H Takizawa, H Salmon, J Idoyaga, ... Journal of Experimental Medicine 212 (2), 281-281, 2015 | 52 | 2015 |
| BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology C Bigenwald, J Le Berichel, CM Wilk, R Chakraborty, ST Chen, ... Nature medicine 27 (5), 851-861, 2021 | 46 | 2021 |
| The immunogenicity of virus-derived 2A sequences in immunocompetent individuals C Arber, H Abhyankar, HE Heslop, MK Brenner, H Liu, G Dotti, B Savoldo Gene therapy 20 (9), 958-962, 2013 | 34 | 2013 |
| Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma R Chakraborty, OA Hampton, H Abhyankar, DJ Zinn, A Grimes, B Skull, ... Oncotarget 8 (28), 46065, 2017 | 30 | 2017 |
| Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH A Sengal, J Velazquez, M Hahne, TM Burke, H Abhyankar, R Reyes, ... Blood, The Journal of the American Society of Hematology 137 (13), 1777-1791, 2021 | 29 | 2021 |
| Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+ CD207+ cells KPH Lim, P Milne, M Poidinger, K Duan, H Lin, N McGovern, H Abhyankar, ... Blood advances 4 (1), 87-99, 2020 | 29 | 2020 |
| IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS H Lin, BP Scull, BR Goldberg, HA Abhyankar, OE Eckstein, DJ Zinn, ... Blood advances 5 (17), 3457-3467, 2021 | 27 | 2021 |
| A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility EC Peckham-Gregory, R Chakraborty, ME Scheurer, JW Belmont, ... Blood, The Journal of the American Society of Hematology 130 (20), 2229-2232, 2017 | 18 | 2017 |
| Defining the inflammatory plasma proteome in pediatric Hodgkin lymphoma JE Agrusa, BP Scull, HA Abhyankar, H Lin, NW Ozuah, R Chakraborty, ... Cancers 12 (12), 3603, 2020 | 8 | 2020 |
| Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E P Milne, H Abhyankar, B Scull, P Singh, R Chakraborty, CE Allen, ... Blood Advances 6 (16), 4901-4904, 2022 | 7 | 2022 |
| Prevalence of the BRAF V600E mutation in Greek adults with Langerhans cell histiocytosis D Stathi, MP Yavropoulou, CE Allen, H Abhyankar, B Scull, M Tsoli, ... Pediatric Hematology and Oncology 39 (6), 540-548, 2022 | 3 | 2022 |
| Immune checkpoint inhibitors restore function of lesion infiltrating T lymphocytes in Langerhans cell histiocytosis R Chakraborty, CE Allen, A Sengal, AS Gaikwad, H Abhyankar, B Scull, ... Blood 130, 2280, 2017 | 3 | 2017 |
